Envista Holdings Corp Stock Price, News & Analysis

Envista Holdings (NYSE: NVST) has released its 2023 Sustainability Report, highlighting significant progress in ESG initiatives. The report showcases notable achievements including a 26% reduction in Scope 1 greenhouse gas emissions and a 3.5% reduction in total emissions intensity. The company maintained 99% gender and ethnic pay equity in the U.S. and donated nearly $1.3 million through the Envista Smile Project.

The report outlines five key focus areas: Delivering Quality and Access, Supporting People and Community, Safeguarding the Environment, Centering Ethics and Compliance, and Practicing Good Governance. Envista implemented several Kaizen projects to enhance sustainability and operational efficiency in waste generation and energy use.

Envista Holdings (NYSE: NVST) has announced its upcoming participation in a fireside chat at the Evercore HealthCONx Conference. The event will take place on Tuesday, December 3, 2024, from 12:30 – 1:15 pm ET at the Loews Coral Gables Hotel in Coral Gables, Florida. An audio-only recording of the session will be available on Envista's Investor Relations website for up to 365 days after the event.

Envista Holdings (NYSE: NVST) reported Q3 2024 financial results with sales of $601.0 million, showing a core sales decline of 5.3% compared to Q3 2023. Net income decreased to $8.2 million ($0.05 per diluted share) from $21.5 million ($0.12 per diluted share) in Q3 2023. Adjusted net income fell to $21.1 million ($0.12 per diluted share) from $75.5 million ($0.43 per diluted share). Adjusted EBITDA decreased to $54.9 million from $123.5 million year-over-year. The company maintains its full-year 2024 guidance of -1% to -4% core sales growth and adjusted EBITDA margins between 10-12%.

Envista Holdings (NYSE: NVST) has announced its upcoming third quarter 2024 earnings call, scheduled for Wednesday, October 30, 2024. The company will report its financial results and host a conference call beginning at 2:00 PM PT, expected to last about an hour.

Investors can access the call and accompanying slide presentation through a webcast on Envista's website in the "Investors" section. A replay will be available shortly after and remain accessible for one year. For those preferring to dial in, the call can be accessed at 800-225-9448 within the U.S. or +1 203-518-9708 internationally, using conference ID #6240897.

Envista will post its earnings press release, webcast slides, and related presentation materials on the company website's "Investors" section prior to the conference call.

DEXIS has announced three new innovations to enhance its digital ecosystem for dental workflows. These include:

• A new X-ray platform, ORTHOPANTOMOGRAPH™ OP 3D™ EX, designed for general practitioners to expand 3D imaging capabilities
• An update to DTX Studio™ Clinic software, enabling faster implant treatment planning and surgical guide generation
• An intraoral scanning software update featuring Oral Compare for visualizing dental issues over time and integration with SmileFy for treatment outcome simulation

These upgrades aim to streamline the implant workflow, provide deeper patient insights, and offer flexible, intuitive solutions for dental professionals.

Envista Holdings (NYSE: NVST) has announced its participation in the Baird 2024 Global Healthcare Conference. The event is scheduled for Wednesday, September 11, 2024, from 10:50 AM to 11:20 AM ET at the InterContinental New York Barclay. Envista's presence at this prominent healthcare conference suggests an opportunity for the company to showcase its developments and engage with industry professionals. However, it's worth noting that no recording link will be available for this event, limiting access to the presentation for those unable to attend in person.

Envista Holdings (NYSE: NVST) reported Q2 2024 results with sales of $633.1 million and a core sales decline of 3.2% compared to Q2 2023. The company posted a net loss of $1,151.6 million ($6.69 per share), including a $1,153.8 million non-cash charge for goodwill and intangible asset impairment. Adjusted net income was $18.5 million ($0.11 per diluted share), down from $76.2 million ($0.43 per diluted share) in Q2 2023. Adjusted EBITDA decreased to $63.0 million from $126.2 million year-over-year.

CEO Paul Keel acknowledged underperformance and outlined steps to reposition the company, including new leadership hires and growth investments. For full-year 2024, Envista expects core sales to decline 1-4% and adjusted EBITDA margins of 10-12%, with further decline in Q3 before returning to growth in Q4.

Envista Holdings (NYSE: NVST) has announced three key leadership appointments, effective in July and August 2024. Eric Hammes joins as Chief Financial Officer, bringing over 25 years of operational and financial leadership experience from Rockwell Automation and 3M. Stefan Nilsson becomes President of Nobel Biocare, with a background as CEO of Colosseum Dental Group and GrandVision Brazil. Veronica Acurio is appointed President of Orthodontics, joining from Solventum with extensive experience in global healthcare businesses, including leadership roles at 3M.

These appointments aim to strengthen Envista's position in dental implants, orthodontics, and overall financial performance. CEO Paul Keel expressed confidence that these leaders will help accelerate growth, expand margins, and advance the company's portfolio in the dental industry.

Envista Holdings (NYSE: NVST) will announce its second quarter 2024 financial results on Wednesday, August 7, 2024. The company has scheduled a conference call for the same day at 2:00 PM PT to discuss these results. The call will include a slide presentation and will be available via webcast on the 'Investors' section of Envista's website. A replay of the webcast will be accessible shortly after the call and will be available for one year. To join the call, dial 800-579-2543 (U.S.) or +1 785-424-1789 (international) and refer to conference ID #9467851. Presentation materials will be available on the company's website before the call.